The primary endpoint of the RADAR-AF trial was freedom from AF off of antiarrhythmic drugs at 6 months. Secondary endpoints included freedom from AF at 1 year and procedural safety outcomes. In brief, the study failed to meet the primary endpoint; indeed, PVI only was superior to HFSA only at 6-month follow-up in patients with paroxysmal AF and was equivalent to PVI plus HFSA in patients with persistent AF. The study, however, did show that HFSA-only ablation reached the secondary endpoint of noninferiority at 1 year compared with PVI alone in patients with paroxysmal AF (79% vs. 81%) and trended toward higher procedure-related complications with PVI (14% vs. 5%).
From the Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. Both authors have reported that they have no relationships relevant to the contents of this paper to disclose. There are a few other considerations regarding the protocol of this important study worth highlighting.
The procedural endpoint adopted for PVI in the RADAR-AF study was entry block, and additional roof linear ablation (without mandatory achievement of conduction block) was performed but at the discretion of the operator. In our experience, demonstration of exit block in addition to entry block is clinically relevant, as unidirectional entry block (with exit conduction) can be observed in up to 20% of PVs (7). Also, no information was provided on This does not imply that PVI per se is not effective as a treatment strategy for AF or that additional non-PV ablation is necessary, because the success rate in the subgroup with permanent PVI is nearly perfect (98%). E-mail: francis.marchlinski@uphs.upenn.edu.
